Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CDH1 | P12830 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461144 | 0.85 | MEN1 (0.54) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL5449783 | 0.85 | DAO (0.48) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL5460248 | 0.85 | L3MBTL1 (0.61) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL5451531 | 0.85 | MEN1 (0.56) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL10925899 | 0.82 | MEN1 (0.61) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL5445324 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL5445311 | 0.82 | PPARD (0.53) | MEN1KMT2ATDP1CYP2C9CYP2C19 | |
| SCHEMBL15932320 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1CDH1CTNNB1 | |
| SCHEMBL17967233 | 0.76 | DAO (0.48) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL15932200 | 0.73 | SMN1; SMN2 (0.57) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | claimed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | claimed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | ARPIDA A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| EP-1664000-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | Arpida A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026133-A1 | ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS | ARPIDA A/S (DK) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043062-A1 | Isoxazoles as peptide deformylase inhibitors | PDF, MRPL21, PEPD | MEN1 1390/4885KMT2A 3828/4885TDP1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.